FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059000312> ?p ?o ?g. }

• W2059000312 endingPage "2195" @default.
• W2059000312 startingPage "2187" @default.
• W2059000312 abstract "BACKGROUND The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma. METHODS Seventy-one Jewish women with epithelial ovarian carcinoma (EOC) were tested for the three BRCA founder mutations using single-strand conformation polymorphism analysis, heteroduplex analysis, and protein truncation testing. Clinical and histopathologic data were reviewed retrospectively. In vitro chemoresistance was analyzed in 32 patients. Mutations of p53 were studied using immunohistochemical detection of p53 overexpression. RESULTS Thirty-four of 71 Jewish patients with EOC (48%) had germline BRCA mutations (BRCA heterozygotes), including 22 BRCA1 mutations and 12 BRCA2 mutations. BRCA heterozygotes were younger compared with Jewish patients who had EOC without mutations (sporadic carcinoma; 50 years vs. 59 years, respectively; P = 0.01). BRCA1 heterozygotes were younger compared with BRCA2 heterozygotes (48 years vs. 57 years, respectively; P = 0.01). Histopathologic tumor features were similar; however, tumors with low malignant potential were seen only in women with sporadic carcinoma. Both groups had equivalent rates of surgical cytoreduction and similar median follow-up (72 months). BRCA heterozygotes had higher response rates to primary therapy compared with patients who had sporadic disease (P = 0.01). In vitro chemoresistance predicted tumor response to platinum chemotherapy correctly in BRCA heterozygotes (P = 0.0096). BRCA heterozygotes with advance-stage disease had improved survival compared with patients who had advanced stage sporadic carcinoma (91 months vs. 54 months, respectively; P = 0.046) and had a longer disease free interval (49 months vs. 19 months, respectively; P = 0.16). p53 overexpression was common in BRCA heterozygotes (80%). CONCLUSIONS BRCA1 heterozygotes developed EOC at a younger age compared with BRCA2 heterozygotes and women who had sporadic ovarian carcinoma. BRCA heterozygotes had a better response to platinum chemotherapy compared with women who had sporadic disease, which may have contributed to their improved prognosis. Cancer 2003;97:2187–95. © 2003 American Cancer Society. DOI 10.1002/cncr.11310" @default.
• W2059000312 created "2016-06-24" @default.
• W2059000312 creator A5002559758 @default.
• W2059000312 creator A5023940537 @default.
• W2059000312 creator A5063682125 @default.
• W2059000312 creator A5075786403 @default.
• W2059000312 creator A5082993956 @default.
• W2059000312 creator A5088516335 @default.
• W2059000312 date "2003-01-01" @default.
• W2059000312 modified "2023-10-03" @default.
• W2059000312 title "Improved survival in women withBRCA-associated ovarian carcinoma" @default.
• W2059000312 cites W1927868261 @default.
• W2059000312 cites W1951483173 @default.
• W2059000312 cites W1961774825 @default.
• W2059000312 cites W1967080458 @default.
• W2059000312 cites W1972710550 @default.
• W2059000312 cites W1973690102 @default.
• W2059000312 cites W1980170092 @default.
• W2059000312 cites W1991148475 @default.
• W2059000312 cites W2000437208 @default.
• W2059000312 cites W2000820980 @default.
• W2059000312 cites W2008233728 @default.
• W2059000312 cites W2008293816 @default.
• W2059000312 cites W2011658104 @default.
• W2059000312 cites W2012053348 @default.
• W2059000312 cites W2019738273 @default.
• W2059000312 cites W2021851245 @default.
• W2059000312 cites W2025460005 @default.
• W2059000312 cites W2038334562 @default.
• W2059000312 cites W2039632729 @default.
• W2059000312 cites W2039832404 @default.
• W2059000312 cites W2044245852 @default.
• W2059000312 cites W2047460928 @default.
• W2059000312 cites W2054139127 @default.
• W2059000312 cites W2057949133 @default.
• W2059000312 cites W2071282471 @default.
• W2059000312 cites W2073315776 @default.
• W2059000312 cites W2073931597 @default.
• W2059000312 cites W2088179903 @default.
• W2059000312 cites W2099521317 @default.
• W2059000312 cites W2103970959 @default.
• W2059000312 cites W2106080156 @default.
• W2059000312 cites W2109764430 @default.
• W2059000312 cites W2117902443 @default.
• W2059000312 cites W2136776823 @default.
• W2059000312 cites W2141563627 @default.
• W2059000312 cites W2143934748 @default.
• W2059000312 cites W2147078287 @default.
• W2059000312 cites W2153926167 @default.
• W2059000312 cites W2154852110 @default.
• W2059000312 cites W2169133611 @default.
• W2059000312 cites W2227161527 @default.
• W2059000312 cites W2305014077 @default.
• W2059000312 cites W2329417450 @default.
• W2059000312 cites W4236554963 @default.
• W2059000312 doi "https://doi.org/10.1002/cncr.11310" @default.
• W2059000312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12712470" @default.
• W2059000312 hasPublicationYear "2003" @default.
• W2059000312 type Work @default.
• W2059000312 sameAs 2059000312 @default.
• W2059000312 citedByCount "411" @default.
• W2059000312 countsByYear W20590003122012 @default.
• W2059000312 countsByYear W20590003122013 @default.
• W2059000312 countsByYear W20590003122014 @default.
• W2059000312 countsByYear W20590003122015 @default.
• W2059000312 countsByYear W20590003122016 @default.
• W2059000312 countsByYear W20590003122017 @default.
• W2059000312 countsByYear W20590003122018 @default.
• W2059000312 countsByYear W20590003122019 @default.
• W2059000312 countsByYear W20590003122020 @default.
• W2059000312 countsByYear W20590003122021 @default.
• W2059000312 countsByYear W20590003122022 @default.
• W2059000312 countsByYear W20590003122023 @default.
• W2059000312 crossrefType "journal-article" @default.
• W2059000312 hasAuthorship W2059000312A5002559758 @default.
• W2059000312 hasAuthorship W2059000312A5023940537 @default.
• W2059000312 hasAuthorship W2059000312A5063682125 @default.
• W2059000312 hasAuthorship W2059000312A5075786403 @default.
• W2059000312 hasAuthorship W2059000312A5082993956 @default.
• W2059000312 hasAuthorship W2059000312A5088516335 @default.
• W2059000312 hasBestOaLocation W20590003121 @default.
• W2059000312 hasConcept C104317684 @default.
• W2059000312 hasConcept C121608353 @default.
• W2059000312 hasConcept C126322002 @default.
• W2059000312 hasConcept C143998085 @default.
• W2059000312 hasConcept C153471976 @default.
• W2059000312 hasConcept C180754005 @default.
• W2059000312 hasConcept C2777546739 @default.
• W2059000312 hasConcept C2780427987 @default.
• W2059000312 hasConcept C3019054536 @default.
• W2059000312 hasConcept C502942594 @default.
• W2059000312 hasConcept C54355233 @default.
• W2059000312 hasConcept C71924100 @default.
• W2059000312 hasConcept C86803240 @default.
• W2059000312 hasConcept C90924648 @default.
• W2059000312 hasConceptScore W2059000312C104317684 @default.
• W2059000312 hasConceptScore W2059000312C121608353 @default.
• W2059000312 hasConceptScore W2059000312C126322002 @default.

• next